Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Aug 31;14(8):2918-2921.
doi: 10.21037/tlcr-2025-442. Epub 2025 Aug 20.

Decoding the immune landscape: KRAS and STK11 genes mutations shape CD8+ T cell response in resectable non-small-cell lung cancer after neoadjuvant therapy

Kamila Wojas-Krawczyk  1 , Magdalena Knetki-Wróblewska  2 , Maciej Krzakowski  2
Affiliations
Editorial

Decoding the immune landscape: KRAS and STK11 genes mutations shape CD8+ T cell response in resectable non-small-cell lung cancer after neoadjuvant therapy

Kamila Wojas-Krawczyk et al. Transl Lung Cancer Res. .
No abstract available

Keywords: CD8 lymphocytes; KRAS; STK11 mutation; resectable non-small cell lung cancer (resectable NSCLC).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-2025-442/coif). M.K.W. reports invited lectures for: MSD, BMS, Roche, Pfizer, Takeda, IPSEN, Astra Zeneca, and Amgen; travel grants: Astra Zeneca, Takeda, MSD, and Pfizer; and participation in advisory committees for: Ipsen, Beigene, and MSD. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Garassino MC, Gadgeel S, Novello S, et al. Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC. JTO Clin Res Rep 2023;4:100431. 10.1016/j.jtocrr.2022.100431 - DOI - PMC - PubMed
    1. Peters S, Cho BC, Luft AV, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial. J Thorac Oncol 2025;20:76-93. 10.1016/j.jtho.2024.09.1381 - DOI - PubMed
    1. West H, Cappuzzo F, Reck M, et al. IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations. Ann Oncol 2020;31:S817-8.
    1. Gandhi MM, Elkrief A, Moore CG, et al. Gene Copy Deletion of STK11, KEAP1, and SMARCA4: Clinicopathologic Features and Association With the Outcomes of Immunotherapy With or Without Chemotherapy in Nonsquamous NSCLC. J Thorac Oncol 2025;20:725-38. 10.1016/j.jtho.2025.01.016 - DOI - PubMed
    1. Sun L, Handorf EA, Zhou Y, et al. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels. Lung Cancer 2024;190:107510. 10.1016/j.lungcan.2024.107510 - DOI - PMC - PubMed

LinkOut - more resources